IGLV3-21<sup>R110</sup> and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.

Hemasphere · 2026 · PMC13266578 · PMID 42306064

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Similarly, the effect of IGLV3‐21 R110 on EFS could not be explained by its association with subset #2, as among all IGLV3‐21 R110 ‐positive patients, those that did not belong to subset #2 showed a trend of having even shorter EFS (Supporting Information S1: Figure S5 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

IGLV3-21&lt;sup&gt;R110&lt;/sup&gt; and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.

The sentences

IGLV3-21<sup>R110</sup> and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.